These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1062 related articles for article (PubMed ID: 31085587)

  • 41. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Down-Regulation of the Androgen Receptor by G-Quadruplex Ligands Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide.
    Tassinari M; Cimino-Reale G; Nadai M; Doria F; Butovskaya E; Recagni M; Freccero M; Zaffaroni N; Richter SN; Folini M
    J Med Chem; 2018 Oct; 61(19):8625-8638. PubMed ID: 30188709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells.
    Dong J; Wu Z; Wang D; Pascal LE; Nelson JB; Wipf P; Wang Z
    Mol Cancer Ther; 2019 Jan; 18(1):39-50. PubMed ID: 30297360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Liu C; Armstrong CM; Ning S; Yang JC; Lou W; Lombard AP; Zhao J; Wu CY; Yu A; Evans CP; Tepper CG; Li PK; Gao AC
    Oncogene; 2021 Sep; 40(35):5379-5392. PubMed ID: 34272475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
    Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
    Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Luk IS; Shrestha R; Xue H; Wang Y; Zhang F; Lin D; Haegert A; Wu R; Dong X; Collins CC; Zoubeidi A; Gleave ME; Gout PW; Wang Y
    Clin Cancer Res; 2017 Mar; 23(6):1542-1551. PubMed ID: 27663589
    [No Abstract]   [Full Text] [Related]  

  • 50. Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.
    de Las Pozas A; Reiner T; De Cesare V; Trost M; Perez-Stable C
    Sci Rep; 2018 Sep; 8(1):13146. PubMed ID: 30177856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.
    Zhang Z; Wang X; Kim M; He D; Wang C; Fong KW; Liu X
    Prostate; 2023 Nov; 83(15):1458-1469. PubMed ID: 37475584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
    Wang K; Luo J; Yeh S; You B; Meng J; Chang P; Niu Y; Li G; Lu C; Zhu Y; Antonarakis ES; Luo J; Huang CP; Xu W; Chang C
    Nat Commun; 2020 Jun; 11(1):2689. PubMed ID: 32483206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
    Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
    Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
    Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.
    Cui Y; Nadiminty N; Liu C; Lou W; Schwartz CT; Gao AC
    Endocr Relat Cancer; 2014 Jun; 21(3):435-42. PubMed ID: 24659479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
    Zhou L; Zhang C; Yang X; Liu L; Hu J; Hou Y; Tao H; Sugimura H; Chen Z; Wang L; Chen K
    Clin Transl Med; 2021 Jun; 11(6):e449. PubMed ID: 34185414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
    Sternberg CN
    Future Oncol; 2019 May; 15(13):1437-1457. PubMed ID: 30848157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
    Xu Y; Song Q; Pascal LE; Zhong M; Zhou Y; Zhou J; Deng FM; Huang J; Wang Z
    Prostate; 2019 May; 79(6):657-666. PubMed ID: 30714180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.